Barrie Charles Finnin
Direktor/Vorstandsmitglied bei PolyActiva Pty Ltd.
Profil
Barrie Charles Finnin is the founder of Acrux Ltd.
which was founded in 1998.
He held the title of Non-Executive Director at Acrux Ltd.
Dr. Finnin's current job is Non-Executive Director at PolyActiva Pty Ltd.
Dr. Finnin's former job was External Evaluator at Therapeutic Goods Administration.
Aktive Positionen von Barrie Charles Finnin
| Unternehmen | Position | Beginn |
|---|---|---|
PolyActiva Pty Ltd.
 PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Barrie Charles Finnin
| Unternehmen | Position | Ende |
|---|---|---|
| ACRUX LIMITED | Gründer | - |
| Therapeutic Goods Administration | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ACRUX LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Therapeutic Goods Administration | |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |